Epoxyeicosatrienoic Acid Analog and 20-HETE Antagonist Combination Prevent Hypertension Development in Spontaneously Hypertensive Rats

FIGURE 1. Time course of (A) systolic blood pressure and (B) heart rates in adult spontaneously hypertensive rats receiving epoxyeicosatrienoic acid analog in two doses at 10 mg/kg/day (n = 6, EET-A) and 40 mg/kg/day (EET-A HD, n = 6); the control group received water (n = 6). Values are expressed as means ± SEM. *p <0.05 vs. baseline values (day 1) within each group by two-way analysis of variance, followed by Bonferroni’s multiple-comparisons test (not significant between groups).

FIGURE 2. (A) Creatinine clearance, ( B ) nitric oxide metabolites excretion, (C) urinary excretion of albumin, and (D) urinary excretion of vascular endothelial growth factor type A measured on days 0, 14, and 28 in adult spontaneously hypertensive rats receiving epoxyeicosatrienoic acid analog in two doses at 10 mg/kg/day (n = 6, EET-A) and 40 mg/kg/day (EET-A HD, n = 6); the control group received water (n = 6). Values are expressed as means ± SEM. *p <0.05 vs. baseline values (day 0) within the EET-A group by two-way analysis of variance, followed by Bonferroni’s multiple-comparisons test; #p <0.05 EET-A vs. EET-A HD at the same time point by two-way analysis of variance, followed by Tukey’s post-hoc test.

FIGURE 3. Time course of (A) systolic blood pressure and (B) heart rates in young spontaneously hypertensive rats receiving epoxyeicosatrienoic acid analog alone (EET-A, n = 7) or combined with 20-HETE receptor antagonist (EET-A + AAA, n = 6), both at a dose of 10 mg/kg/day; the control group received water (n = 7). Values are expressed as means ± SEM. *p <0.05 vs. baseline values (day 1) within each group by two-way analysis of variance, followed by Bonferroni’s multiple-comparisons test; #p <0.05 EET-A + AAA vs. EET-A and the control group at the same time point by two-way analysis of variance, followed by Tukey’s post-hoc test.

FIGURE 4. (A) Creatinine clearance, (B) nitric oxide metabolite excretion, (C) urinary excretion of albumin, and (D) urinary excretion of vascular endothelial growth factor type A measured on days 0, 14, and 28 in young spontaneously hypertensive rats receiving epoxyeicosatrienoic acid analog alone (EET-A, n = 7) or combined with 20-HETE receptor antagonist (EET-A + AAA, n = 6), both at a dose of 10 mg/kg/day; the control group received water (n = 7). *p <0.05 vs. baseline values (day 0) within each group by two-way analysis of variance, followed by Bonferroni’s multiple-comparisons test; #p <0.05 EET-A + AAA vs. EET-A and the control group at the same time point by two-way analysis of variance, followed by Tukey’s post-hoc test.